Nuevolution

May 22, 2019

Statement by the Board of Directors of Nuevolution in Relation to the Public Offer From Amgen

May 22, 2019

Amgen announces a recommended public cash offer to the shareholders of Nuevolution

May 22, 2019

Nuevolution AB (publ) Announces its Results for the First Quarter of 2019

Aug 22, 2018

Nuevolution Discloses the Identity of its "Cytokine X" Program being Interleukin IL-17A and Initiates Promotion of its Small Molecule IL-17A Inhibitor Program Targeting Inflammatory Diseases

Jan 23, 2018

Nuevolution Appoint Dr. Paul Scigalla as Chief Medical Officer on Consultancy Basis

Jan 04, 2018

Nuevolution to Receive License Fee Payment of USD 750,000

Nov 27, 2017

Nuevolution to Present New Data on its BET BD1 Program Supporting Effect in Psoriasis/Atopic Dermatitis

Nov 06, 2017

Nuevolution Appoints Johnny Stilou as Director of Investor Relations and Corporate Communication

Sep 06, 2017

Nuevolution AB (publ) Announces its Results for the Fourth Quarter and Full Year 2016/17

Jun 19, 2017

Nuevolution Presents Additional Positive Animal Results in Lupus From its BET Selective Program

Jun 12, 2017

Nuevolution to Present at Anglo-Nordic Medicinal Chemistry Symposium